Einzeltreffer — DigiBib

Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG; TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP; CCATSGPCGAVMILTPHLTA; MTLTTGSGAIAPAMPPGLPPHTGAIHAPM; and NXVPVSVEGYXQITLDSITX and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.

Titel:	Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells
Autor/in / Beteiligte Person:	Zhabilov, Harry H.
Link:	Zum Volltext
Veröffentlichung:	2010
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20100143291 Publication Date: June 10, 2010 Appl. No: 12/315441 Application Filed: December 02, 2008 Claim: 1. An isolated irreversibly inactivated anti-cancer pepsin characterized by the amino acid sequence of SEQ ID: NO. 1 Claim: 2. A composition comprising the isolated irreversibly inactivated anti-cancer pepsin of claim 1, further comprising a carri Claim: 3. A composition for inferring immunity against malignant human cells, said composition comprising the composition of claim 2 combined with IL2 Claim: 4. A therapeutic composition comprising a complex of the composition of claim 1 bound to human gp96. Claim: 5. A therapeutic composition comprising a complex of the composition of claim 1 bound to a receptor disposed on human gp96. Claim: 6. The composition of claim 5, where in the receptor is CD91. Claim: 7. A 45 kD pepsinogen fragment consisting of the isolated irreversibly inactivated anti-cancer pepsin of claim 1, wherein said pepsinogen fragment has a binding affinity for human gp96. Claim: 8. A composition comprising the therapeutic composition of claim 4, said composition further comprising IL2. Claim: 9. An isolated irreversibly inactivated anti-cancer pepsin characterized by the amino acid sequence of SEQ ID: NO. 2. Claim: 10. A composition comprising the isolated irreversibly inactivated anti-cancer pepsin of claim 9, further comprising a carrier. Claim: 11. A therapeutic composition comprising a complex of the composition of claim 9 bound to human gp96. Claim: 12. A composition comprising the therapeutic composition of claim 11, said composition further comprising IL2. Claim: 13. A thirty one amino acid pepsinogen fragment having a binding affinity for human gp96. Claim: 14. An isolated irreversibly inactivated anti-cancer pepsin characterized by the amino acid sequence of SEQ ID: NO. 3. Claim: 15. A composition comprising the isolated irreversibly inactivated anti-cancer pepsin of claim 14, further comprising a carrier. Claim: 16. A therapeutic composition comprising a complex of the composition of claim 14 bound to human gp96. Claim: 17. The therapeutic composition of claim 16, wherein the irreversibly inactivated anti-cancer pepsin of claim has a molecular weight of approximately 13.5 kD. Claim: 18. The composition of claim 16 further comprising IL2. Claim: 19. A composition comprising an IPF gp96 complex, wherein said composition demonstrates superantigen activity. Claim: 20. A complex of gp96 and IPF, wherein the complex activates major histocompatibility complex (HMC)-restricted manner. Claim: 21. An isolated irreversibly inactivated anti-cancer pepsin characterized by the amino acid sequence of SEQ ID: NO. 4. Claim: 22. A composition comprising the isolated irreversibly inactivated anti-cancer pepsin of claim 21, further comprising a carrier. Claim: 23. A therapeutic composition comprising a complex of the composition of claim 21 bound to human gp96. Claim: 24. An isolated irreversibly inactivated anti-cancer pepsin characterized by the amino acid sequence of SEQ ID: NO. 5. Claim: 25. A composition comprising the isolated irreversibly inactivated anti-cancer pepsin of claim 24, further comprising a carrier. Claim: 26. A therapeutic composition comprising a complex of the composition of claim 24 bound to human gp96. Claim: 27. The composition of claim 26, further comprising IL2. Claim: 28. A method of treating cancer, said method comprising the step of administering to a patient the therapeutic composition of claim 4. Claim: 29. A method of treating cancer, said method comprising the step of administering to a patient the therapeutic composition of claim 11. Claim: 30. A method of treating cancer, said method comprising the step of administering to a patient the therapeutic composition of claim 16. Claim: 31. A method of treating cancer, said method comprising the step of administering to a patient the therapeutic composition of claim 23. Claim: 32. A method of treating cancer, said method comprising the step of administering to a patient the therapeutic composition of claim 26. Current U.S. Class: 424/852 Current International Class: 61; 12; 61

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells